Ophthalmic Composition for Treating Myopia

According to GlobalData’s company profile on Rohto Pharmaceutical, Nanoemulsion cosmetics was a key innovation area identified from patents. Rohto Pharmaceutical‘s grant share as of January 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.

Ophthalmic composition for treating myopia with crocetin and ginkgo leaf

A recently granted patent (Publication Number: US11813299B2) discloses a method for treating axial myopia in humans by administering a therapeutically effective amount of crocetin. The method involves administering crocetin at a dosage ranging from 0.075 to 75 mg/day to effectively treat axial myopia, particularly high myopia. Additionally, the method may include administering other carotenoids or polyphenols, excluding ginkgo leaf extract, to individuals in need of treatment.

Furthermore, the patent claims that administering crocetin can inhibit ocular axial elongation and enhance EGR-1 expression, particularly when administered to children during growth. The method is targeted towards individuals who are near workers or indoor workers, suggesting a potential application for those who spend extended periods focusing on close-up tasks. Overall, the patent highlights the potential of crocetin as a therapeutic agent for treating axial myopia and its associated mechanisms of action in the human eye.

To know more about GlobalData’s detailed insights on Rohto Pharmaceutical, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies